Haemonetics Stock Number Of Employees
| HAE Stock | USD 77.41 0.23 0.30% |
Haemonetics fundamentals help investors to digest information that contributes to Haemonetics' financial success or failures. It also enables traders to predict the movement of Haemonetics Stock. The fundamental analysis module provides a way to measure Haemonetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Haemonetics stock.
Haemonetics |
Haemonetics Company Number Of Employees Analysis
Haemonetics' Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Current Haemonetics Number Of Employees | 3.66 K |
Most of Haemonetics' fundamental indicators, such as Number Of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Haemonetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
| Competition |
Based on the recorded statements, Haemonetics is currently employing 3.66 K people. This is 66.75% lower than that of the Health Care Equipment & Supplies sector and 50.64% lower than that of the Health Care industry. The number of employees for all United States stocks is 80.59% higher than that of the company.
Haemonetics Number Of Employees Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Haemonetics' direct or indirect competition against its Number Of Employees to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Haemonetics could also be used in its relative valuation, which is a method of valuing Haemonetics by comparing valuation metrics of similar companies.Haemonetics is currently under evaluation in number of employees category among its peers.
Haemonetics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Haemonetics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Haemonetics' managers, analysts, and investors.Environmental | Governance | Social |
Haemonetics Fundamentals
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0588 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 4.81 B | ||||
| Shares Outstanding | 50.22 M | ||||
| Shares Owned By Insiders | 0.89 % | ||||
| Shares Owned By Institutions | 99.11 % | ||||
| Number Of Shares Shorted | 4.57 M | ||||
| Price To Earning | 50.35 X | ||||
| Price To Book | 4.42 X | ||||
| Price To Sales | 2.86 X | ||||
| Revenue | 1.31 B | ||||
| Gross Profit | 530.77 M | ||||
| EBITDA | 265.58 M | ||||
| Net Income | 117.56 M | ||||
| Cash And Equivalents | 284.47 M | ||||
| Cash Per Share | 4.79 X | ||||
| Total Debt | 807.79 M | ||||
| Debt To Equity | 1.12 % | ||||
| Current Ratio | 2.73 X | ||||
| Book Value Per Share | 17.44 X | ||||
| Cash Flow From Operations | 181.75 M | ||||
| Short Ratio | 6.33 X | ||||
| Earnings Per Share | 2.41 X | ||||
| Price To Earnings To Growth | 1.25 X | ||||
| Target Price | 110.8 | ||||
| Number Of Employees | 3.66 K | ||||
| Beta | 0.32 | ||||
| Market Capitalization | 3.89 B | ||||
| Total Asset | 2.2 B | ||||
| Retained Earnings | 360.46 M | ||||
| Working Capital | 468.52 M | ||||
| Current Asset | 488.09 M | ||||
| Current Liabilities | 185.55 M | ||||
| Net Asset | 2.2 B |
About Haemonetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Haemonetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Haemonetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Haemonetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:Check out Haemonetics Piotroski F Score and Haemonetics Altman Z Score analysis. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.375 | Earnings Share 2.41 | Revenue Per Share 26.77 | Quarterly Revenue Growth 0.086 | Return On Assets 0.0588 |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.